Delivering therapeutic lysosomal enzyme to the CNS: A rapid, large-scale in vivo screen identifies optimal characteristics of BBB-crossing TFRC antibodiesMOLECULAR GENETICS AND METABOLISMIF3.52023-02-011PRE
BBB-targeted GAA delivered as gene therapy treats CNS and muscle in Pompe disease model miceMOLECULAR GENETICS AND METABOLISMIF3.52022-02-010PRE
Cell type-selective targeted delivery of a recombinant lysosomal enzyme for enzyme therapiesMOLECULAR THERAPYIF122021-12-0115OAAI
Human B Cell Differentiation Is Characterized by Progressive Remodeling of O-Linked GlycansFRONTIERS IN IMMUNOLOGYIF5.92018-12-1435OAAI
Galectin-Glycan Interactions as Regulators of B Cell ImmunityFRONTIERS IN IMMUNOLOGYIF5.92018-12-0436OAAI
Loss of GCNT2/I-branched glycans enhances melanoma growth and survivalNATURE COMMUNICATIONSIF15.72018-08-2243OAAI
Galectin-9 suppresses B cell receptor signaling and is regulated by I-branching of N-glycansNATURE COMMUNICATIONSIF15.72018-08-1791OAAI
Protective Immunity against Chlamydia trachomatis Can Engage Both CD4+ and CD8+ T Cells and Bridge the Respiratory and Genital MucosaeJOURNAL OF IMMUNOLOGYIF3.42015-03-0136OAAI